La evidencia clínica que respalda FontUp®

FontUp® ha sido evaluado en un ensayo clínico de referencia, el estudio PENSA. En este estudio se evaluó su eficacia en personas con riesgo de desarrollar Alzheimer en el marco de una intervención multimodal en el estilo de vida.

Los resultados aportan evidencia sobre su interés en el ámbito de la intervención temprana del deterioro cognitivo.

Clinically proven

FontUp® has demonstrated cognitive benefits in people at risk of developing Alzheimer's disease.

The PENSA study evaluated FontUp® within the framework of a multimodal lifestyle intervention that included: Mediterranean diet, physical exercise, and cognitive stimulation
Improved cognitive performance

After 12 months, the group that received FontUp® showed a 50% greater improvement in overall cognition compared to the placebo group. Furthermore, almost half of the participants treated with FontUp® (48%) improved their cognitive performance, compared to 27% in the placebo group.

Sustained effect over time

The benefits observed in cognitive function were maintained even three months after the intervention ended, indicating a persistent effect beyond the period of consumption.

It reduces the risk of developing dementia

In one year of intervention with FontUp® , the risk of developing dementia was reduced by 25%, as assessed by the LIBRA Index, a validated tool for estimating long-term dementia risk.

EGCG: the active ingredient in FontUp®

Epigallocatechin-3-gallate (EGCG) is the main bioactive polyphenol in green tea and one of the most studied natural compounds in the field of brain health.

FontUp® incorporates EGCG in a formulation designed to protect cognitive health from early stages.

It promotes communication between neurons and synaptic plasticity

EGCG helps maintain neural connections, a key element for memory and learning.

Zhang et al., 2020

It reduces brain inflammation and oxidative stress

EGCG modulates pro-inflammatory cytokines and activates natural antioxidant pathways that protect neurons from damage.

Valverde-Salazar et al., 2023.

Subheading

Image with text

Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.

Button text

It reduces the accumulation of toxic proteins involved in Alzheimer's disease.

In preclinical models, EGCG promotes pathways that decrease the accumulation of β-amyloid and tau, both of which are involved in Alzheimer's disease.

Rezai-Zadeh et al., 2005.

It regulates key proteins related to Alzheimer's disease.

EGCG inhibits the DYRK1A protein, which is involved in the accumulation of beta-amyloid and tau, processes associated with cognitive decline.

Yin et al., 2017.

Protect your cognitive health starting today.

FontUp® has demonstrated cognitive benefits in people at risk of developing Alzheimer's.

  • 100 mg EGCG/capsule
  • Gluten-free, caffeine-free, and calorie-free
  • Safe and well tolerated
Buy FontUp
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
Reduces the risk of dementia
·

Clinical evidence that supports FontUp®

FontUp® has a proven track record of clinical research in the field of cognitive health and has been validated by three clinical studies. The most recent, the PENSA study , is the main pillar of evidence in populations at risk of developing Alzheimer's disease.

PENSA Study

A multimodal lifestyle intervention complemented with epigallocatechin gallate to prevent cognitive decline in APOE- ɛ4 carriers with Subjective Cognitive Decline: a randomized, double-blinded clinical trial

The PENSA study is a randomized, double-blind, controlled clinical trial conducted in individuals with subjective cognitive impairment and a high risk of developing Alzheimer's disease. Its objective was to evaluate an early intervention strategy in the initial stages of cognitive decline.

Based on the multidomain model of the FINGER study - which combines Mediterranean diet, physical exercise and cognitive stimulation - PENSA integrated the FontUp® assessment within this structured approach.

The robustness of its design and the use of validated assessment tools reinforce the scientific consistency of the study and its relevance in the field of cognitive health.

View full study

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomized, placebo-controlled, phase 2 trial

The TESTAD study is a randomized, double-blind, controlled clinical trial that evaluated the effect of FontUp® in adults with Down syndrome, a population with special cognitive vulnerability and a higher risk of developing early-onset Alzheimer's disease.

It demonstrated improvements in certain cognitive functions, especially in areas related to executive function and memory.

View full study

Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)

The PERSEUS study is a clinical trial designed to further evaluate FontUp® in people with Down syndrome, using structured follow-up and neuropsychological tools adapted to this population.

The results provided further evidence on the role of FontUp® in the cognitive environment, confirming its good tolerability and reinforcing the scientific basis for its further evaluation in other populations with cognitive vulnerability.

View full study

Other studies

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG); Zhang et al., 2020

In animal models of Alzheimer's disease, EGCG improves memory and cognitive function, effects associated with reduced β-amyloid accumulation and oxidative stress. These changes help preserve neuronal integrity and synaptic connections, which are key to learning and memory.

Alzheimer's Disease and Green Tea: Epigallocatechin-3-Gallate as a Modulator of Inflammation and Oxidative Stress; Valverde-Salazar et al., 2023

The reviewed evidence indicates that EGCG modulates key inflammatory pathways and strengthens antioxidant defenses in neurons and glial cells. These effects contribute to reducing cell damage associated with Alzheimer's disease.

Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer's Transgenic Mice; Rezai-Zadeh et al., 2005

In transgenic Alzheimer's mice, treatment with EGCG reduces the accumulation of β-amyloid plaques and modulates tau pathology. These changes are accompanied by a significant improvement in cognitive performance.

Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice; EGCG treatment normalizes tau splicing and rescues cognitive performance; Yin et al., 2017

This study demonstrates that EGCG inhibits the DYRK1A enzyme, normalizes tau protein processing, and reverses cognitive deficits in a mouse model with Alzheimer's-like disorders.

Frequently Asked Questions

What clinical study supports FontUp®?

FontUp® was evaluated in the PENSA clinical study, a trial conducted in individuals with subjective memory complaints and an increased risk of developing Alzheimer's disease. The study analyzed the impact of an early intervention over 12 months, combining a structured healthy lifestyle program with FontUp® supplementation, with the aim of assessing changes in cognitive performance and risk indicators.
What was the design of the PENSA clinical trial?

The PENSA study is a randomized, double-blind, placebo-controlled clinical trial. Participants were assessed using standardized neuropsychological tools and validated scales to measure global cognition and dementia risk. This design allowed for a rigorous comparison of outcomes between the FontUp® group and the placebo group within the same lifestyle intervention program.
What results were observed in cognitive performance?

After 12 months of intervention, the group that received FontUp® showed a 50% greater improvement in overall cognition compared to the placebo group.

Cognitive performance was assessed using the PACC-Exe (Preclinical Alzheimer Cognitive Composite – Executive Function), a composite battery designed to detect subtle changes in early stages of cognitive decline, particularly in executive functions and memory.

Furthermore, 48% of participants who received EGCG improved their cognitive performance, compared to 27% in the placebo group, suggesting a differential effect associated with supplementation within the context of early intervention.
Were any effects observed on the risk of dementia?

Yes. In addition to the improvement in cognitive performance, the study showed a reduction in the estimated risk of dementia.

This risk was assessed using the LIBRA (Lifestyle for Brain Health Index), a validated tool that estimates the modifiable risk of dementia based on lifestyle and health factors.

The results support the interest in intervening in early stages, when the process has not yet been consolidated from a clinical point of view.
How does FontUp® differ from other memory products?

FontUp® stands out because it has its own clinical research, including randomized, double-blind, and controlled trials, considered the standard of quality in science.

It has been evaluated in people with Down syndrome (TESTAD and PERSEUS studies) as well as in people with subjective cognitive impairment and high risk of Alzheimer's within the PENSA Study, based on the multidomain model of the FINGER study.

Unlike many memory products, its development is based on a structured scientific foundation and validated assessment tools in the field of cognitive health.
What scientific evidence supports the use of EGCG?

Epigallocatechin-3-gallate (EGCG) is one of the most studied polyphenols in green tea in the field of brain health. The scientific literature includes preclinical studies and experimental models that have described its effects on processes such as oxidative stress, inflammation, and synaptic plasticity. This body of evidence has generated interest in its application within preventive strategies aimed at the early stages of cognitive decline.

Subheading

Collapsible content

Add a short description for this section

Collapsible row

Fill in the text content of the collapsible item here. You can provide details and explanation for the question here.